Exploring metabolic vulnerability and therapeutic potential in cancers with isocitrate dehydrogenase mutations
<p>Treatment of mutant isocitrate dehydrogenase 1 (IDH1) glioma remains challenging; targeted allosteric inhibitors currently provide limited clinical effect. Resistance to mutIDH1 inhibitors has also emerged in other cancers with mutant <em>IDH1</em>. IDH1 catalyses the decarboxyl...
| Autor principal: | |
|---|---|
| Otros Autores: | |
| Formato: | Tesis |
| Lenguaje: | Englihs |
| Publicado: |
2022
|
| Materias: |